德克萨斯大学MD安德森癌症中心胶质母细胞瘤患者的临床试验参与情况
回顾性分析2007至2012年MD安德森癌症中心755例原发性胶质母细胞瘤成人患者,其中511例参与临床试验(新诊断311例、复发200例),133例不符合条件、111例符合条件但接受标准治疗;参与与否在就业状况、教育、症状、肿瘤位置、体能状态、切除范围和治疗机构方面存在差异。
要点
- 755例原发性胶质母细胞瘤患者中511例参与临床试验,133例不符合条件,111例符合条件但未入组。
- 新诊断试验参与者多为男性(65.1%)、白人(86.3%)、已婚(84.4%)和州内居民(59.9%)。
- 符合条件但未入组者倾向年龄更大、体能状态更差、居住地离MD安德森更远。
核心结论
- 胶质母细胞瘤患者临床试验入组存在诸多疾病和人口学障碍,需关注这些障碍以改善入组。
研究设计与样本
- 回顾性分析2007年至2012年在德克萨斯大学MD安德森癌症中心接受治疗的原发性胶质母细胞瘤成人患者记录,共识别755例。
主要发现
- 755例中133例被认为不符合条件,111例符合条件但接受标准治疗,511例参与临床试验(新诊断311例,复发200例)。
- 临床试验参与者和符合条件患者的中位年龄为53.2岁(标准差12.1)。
- 49.4%的患者入组新诊断胶质母细胞瘤临床试验方案。
- 新诊断试验参与者中男性占65.1%、白人占86.3%、已婚占84.4%、州内居民占59.9%。
- 新诊断试验参与者与非参与者在就业状况、教育、症状、肿瘤位置、体能状态、切除范围和治疗机构方面存在差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It is estimated only 8-11% of patients with glioblastoma (GBM) enrol in clinical trials, limiting treatment development. We analysed the clinical and demographic features of patients with GBM enroled in clinical trials at the University of Texas MD Anderson Cancer Center (MDACC). METHODS: We reviewed the records of adult patients treated for primary GBM between 2007 and 2012 at the MDACC. A total of 755 patients were identified: 133 were deemed non-eligible, 111 were deemed trial eligible but received standard care and 511 participated in a clinical trial (311 for newly diagnosed glioblastoma [nGBM] and 200 for recurrent glioblastoma [rGBM]). Population characteristics were analysed using descriptive statistics, and survival end-points were evaluated with the Kaplan-Meier method. RESULTS: The median age of clinical trial participants and trial eligible patients was 53.2 years (standard deviation 12.1). Most patients (49.4%) were enroled in a clinical trial protocol for nGBM. The majority of nGBM trial participants were male patients (65.1%), white (86.3%), married (84.4%) and in state (59.9%). Employment status, education, symptoms, tumour location, performance status, extent of resection and treatment facility differed between nGBM trial participants and non-participants. Patients who were eligible but did not enrol tended to be older, have worse performance status and live farther away from the MDACC. CONCLUSION: Numerous disease and demographic barriers exist in trial enrolment in patients with GBM. This study highlights some of these obstacles, which require attention to improve patient enrolment to clinical trials. Patient and physician engagement in novel therapeutic strategies is essential to improving outcomes in this disease.
引用
- Harrison RA, Anderson MD, Cachia D, et al. Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center. Eur J Cancer. 2019. PMID: 30951926. doi:10.1016/j.ejca.2019.02.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。